

IPA to host 9th edition of Global Pharmaceutical Quality Summit

Theme: 'Advances in Manufacturing and Quality – Patient Centricity'

Two-day flagship event on 27-28 June 2024 in Mumbai; Top industry leaders expected to attend

Mumbai, 12th June 2024: The Indian Pharmaceutical Alliance (IPA) is all set to host the Ninth edition of the Global Pharmaceutical Quality Summit, on 27-28 June 2024 in Mumbai. The theme for this year's Summit is - Advances in Manufacturing and Quality – Patient Centricity. The Summit showcases sessions that explore how the industry can leverage technology to build the next decade for pharmaceutical operations and manufacturing.

Nilesh Gupta, Chair of the Quality Forum at IPA, and Managing Director of Lupin will inaugurate the Summit, which will be attended by stakeholders from the government, industry, and global experts. This will be followed by the release of a report titled **Shaping the Next Decade of Indian Pharmaceutical Manufacturing**.

The Summit will bring together speakers from key global regulators such as DCGI, USFDA, MHRA, WHO industry leaders, academia, and experts to share their perspectives on topics of importance in quality management, and related regulatory updates. With an impressive lineup of speakers and panelists, the summit promises deep insights into the evolving landscape of pharmaceutical manufacturing.

The Summit will cover a range of strategic topics keeping in perspective the current and future trends in Quality and Manufacturing such as the Future of Pharma Operations, Cybersecurity, the Use of AI in Pharmaceutical Quality and Operations, Opportunities in Biopharma and Smart Operations. The participants will gain deeper insights on recent focus areas such as Quality Management Maturity Models, Data and Documentation Imperative and Talent Capability Building. Guidance documents on Good Engineering Practices and Process Analytical Technology (PAT) in Orals Solids and API will also be released in the Summit.

Mr Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance, said, *"The Indian pharmaceutical industry is undergoing a transformative era marked by advancements in manufacturing such as continuous manufacturing, green chemistry and 3D printing. These initiatives must prioritize patient-centricity. By focusing on patient needs in design and manufacturing, India will further cement its position as 'The Pharmacy of the World'. Quality is a fundamental tenet of the pharmaceutical sector. IPA is committed to making India the global quality benchmark. The 9th GPQS summit is a step to bring domain experts, global regulators, and industry at one platform to drive discussions on key priorities to define the next decade for*

pharmaceutical operations and manufacturing”.

The knowledge partner for the Summit is McKinsey & Company. The Summit's most coveted session is the panel discussion comprising industry captains of leading pharma companies to deliberate on charting the next decade of pharmaceutical operations and manufacturing.

About IPA:

IPA represents 23 research-based national pharmaceutical companies. Collectively, IPA companies account for over 85 percent of the private sector investment in pharmaceutical research and development. They contribute more than 80 per cent of the country's exports of drugs and pharmaceuticals and service over 64 percent of the domestic market.

For more information, visit <https://www.ipa-india.org/>
For media queries, please contact:

Aniket Singh Saran: 95604 76715
aniket@avianwe.com

Nisha Boruah: 7836911132
nishab@avianwe.com